Volume 11 Issue 3
May  2020
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2020  >  11(3): 350-355
Liang Ziming, Ye Linsen, Tang Hui, et al. Evaluation of clinical prognosis of liver transplant recipients of hepatocellular carcinoma complicated with microvascular invasion[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 350-355. doi: 10.3969/j.issn.1674-7445.2020.03.005
Citation: Liang Ziming, Ye Linsen, Tang Hui, et al. Evaluation of clinical prognosis of liver transplant recipients of hepatocellular carcinoma complicated with microvascular invasion[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 350-355. doi: 10.3969/j.issn.1674-7445.2020.03.005
shu

Evaluation of clinical prognosis of liver transplant recipients of hepatocellular carcinoma complicated with microvascular invasion

doi: 10.3969/j.issn.1674-7445.2020.03.005

  • Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

More Information
  • Corresponding author: Yi Shuhong, Email: yishuhong@163.com
  • Received Date: 2020-01-30
    Available Online: 2021-01-19
  • Publish Date: 2020-05-15
    Abstract
  •   Objective  To investigate the clinical prognosis of the liver transplant recipients diagnosed with hepatocellular carcinoma (HCC) complicated with microvascular invasion (MVI).  Methods  Clinical data of 3 447 HCC recipients undergoing liver transplantation were extracted from Surveillance, Epidemiology, and End Results (SEER) database of American National Cancer Institute. According to the incidence of MVI, all recipients were divided into MVI (n=376) and non-MVI groups (n=3 071). The clinical prognosis of liver transplant recipients was statistically compared between two groups by analyzing the 1-, 3- and 5-year overall survival (OS) and liver cancer specific survival (LCSS). Relevant clinical data including age, gender, race, pathological staging, tumor size, lymph node metastasis, distant metastasis, tumor-node-metastasis (TNM) staging and MVI were recorded in two groups. The independent risk factors of clinical prognosis of HCC recipients undergoing liver transplantation were analyzed by multivariate Cox regression model. The nomogram for predicting the clinical prognosis of the recipients was delineated. The accuracy of the prediction model was evaluated by the consistency index.  Results  In the non-MVI group, the 1-, 3-, 5-year OS and LCSS were 93.5%, 82.1%, 75.3% and 98.3%, 93.8%, 90.7%, significantly higher than 88.8%, 72.1%, 68.4% and 95.3%, 83.1%, 80.4% in the MVI group (all P < 0.05). Multivariate regression analysis showed that pathological staging, tumor size, lymph node metastasis, distant metastasis, TNM staging and MVI were the independent risk factors of OS and LCSS in HCC recipients undergoing liver transplantation (all P < 0.05). The nomogram consistency index was calculated as 0.624 (0.602-0.648).  Conclusions  MVI is an independent risk factor of the clinical prognosis of HCC recipients undergoing liver transplantation, which is significantly correlated with poor prognosis of the recipients. The nomogram based on MVI can predict the clinical prognosis of these recipients.

     

    • FullText(HTML)
  • loading
    • References(26)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI: 10.3322/caac.21492.
    [2]
    YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604. DOI: 10.1038/s41575-019-0186-y.
    [3]
    谭晓宇, 陈晓兰, 林金铭, 等.机械灌注技术引领器官捐献与移植模式的变革——器官ICU时代即将到来?[J].器官移植, 2019, 10(4):453-458.DOI:10.3969/j.issn. 1674-7445.2019.04.018.

    TAN XY, CHEN XL, LIN JM, et al. Mechine perfusion technology leads the transformation of organ donation and transplantation model: the age of organ ICU?[J]. Organ Transplant, 2019, 10(4):453-458. DOI: 10.3969/j.issn.1674-7445.2019.04.018.
    [4]
    POMMERGAARD HC, ROSTVED AA, ADAM R, et al. Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry[J]. HPB (Oxford), 2018, 20(8):768-775. DOI: 10.1016/j.hpb.2018.03.002.
    [5]
    胡月雷, 孙大伟, 骆飞翔, 等.单发肝细胞癌发生微血管侵犯的影响因素及预后分析[J].临床肝胆病杂志, 2018, 34(9):1911-1916.DOI: 10.3969/j.issn.1001-5256.2018.09.017.

    HU YL, SUN DW, LUO FX, et al. Influencing factors for microvascular invasion in patients with single hepatocellular carcinoma and their prognosis[J]. J Clin Hepatol, 2018, 34(9):1911-1916. DOI:10.3969/j.issn. 1001-5256.2018.09.017.
    [6]
    SUMIE S, KUROMATSU R, OKUDA K, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors[J]. Ann Surg Oncol, 2008, 15(5):1375-1382. DOI: 10.1245/s10434-008-9846-9.
    [7]
    SAYINER M, GOLABI P, YOUNOSSI ZM. Disease burden of hepatocellular carcinoma: a global perspective[J]. Dig Dis Sci, 2019, 64(4):910-917. DOI: 10.1007/s10620-019-05537-2.
    [8]
    BERTUCCIO P, TURATI F, CARIOLI G, et al. Global trends and predictions in hepatocellular carcinoma mortality[J]. J Hepatol, 2017, 67(2):302-309. DOI: 10.1016/j.jhep.2017.03.011.
    [9]
    XU X, CHEN J, WEI Q, et al. Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition) [J]. Hepatobiliary Pancreat Dis Int, 2019, 18(4):307-312. DOI: 10.1016/j.hbpd.2019.06.010.
    [10]
    BENSON AB, D'ANGELICA MI, ABBOTT DE, et al. Guidelines insights: hepatobiliary cancers, version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4):302-310. DOI: 10.6004/jnccn.2019.0019.
    [11]
    GALLE PR, FORNER A, LLOVET JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019.
    [12]
    AZOULAY D, AUDUREAU E, BHANGUI P, et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma: a multicenter, western, intent-to-treat cohort study[J]. Ann Surg, 2017, 266(6):1035-1044. DOI: 10.1097/SLA.0000000000001986.
    [13]
    ASSALINO M, TERRAZ S, GRAT M, et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion[J]. Transpl Int, 2020, DOI: 10.1111/tri.13586 [Epub ahead of print].
    [14]
    YE L, KRIEGL L, REITER FP, et al. Prognostic significance and functional relevance of olfactomedin 4 in early-stage hepatocellular carcinoma[J]. Clin Transl Gastroenterol, 2020, 11(1):e00124. DOI: 10.14309/ctg.0000000000000124.
    [15]
    SHEN JY, LI C, WEN TF, et al. Liver transplantation versus surgical resection for HCC meeting the Milan criteria: a propensity score analysis[J]. Medicine (Baltimore), 2016, 95(52):e5756. DOI: 10.1097/MD.0000000000005756.
    [16]
    LI X, HUANG L, LENG X. Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation[J]. J Cancer Res Clin Oncol, 2018, 144(12):2465-2474. DOI: 10.1007/s00432-018-2756-8.
    [17]
    LAHAN-MARTINS D, PERALES SR, GALLANI SK, et al. Microvascular invasion in hepatocellular carcinoma: is it predictable with quantitative computed tomography parameters? [J]. Radiol Bras, 2019, 52(5):287-292. DOI: 10.1590/0100-3984.2018.0123.
    [18]
    ANDREOU A, BAHRA M, SCHMELZLE M, et al. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation[J]. Clin Transplant, 2016, 30(7):819-827. DOI: 10.1111/ctr.12755.
    [19]
    EGUCHI S, TAKATSUKI M, HIDAKA M, et al. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection[J]. World J Surg, 2010, 34(5):1034-1038. DOI: 10.1007/s00268-010-0424-5.
    [20]
    GOH BK, CHOW PK, TEO JY, et al. Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma[J]. J Gastrointest Surg, 2014, 18(8):1477-1485. DOI: 10.1007/s11605-014-2542-0.
    [21]
    YANG P, SI A, YANG J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery, 2019, 165(4):721-730. DOI: 10.1016/j.surg.2018.09.016.
    [22]
    GIARD JM, MEHTA N, DODGE JL, et al. Alpha-fetoprotein slope > 7.5 ng/ml per month predicts microvascular invasion and tumor recurrence after liver transplantation for hepatocellular carcinoma[J]. Transplantation, 2018, 102(5):816-822. DOI: 10.1097/TP.0000000000002094.
    [23]
    IGUCHI T, SHIRABE K, AISHIMA S, et al. New pathologic stratification of microvascular invasion in hepatocellular carcinoma: predicting prognosis after living-donor liver transplantation[J]. Transplantation, 2015, 99(6):1236-1242. DOI: 10.1097/TP.0000000000000489.
    [24]
    NITTA H, ALLARD MA, SEBAGH M, et al. Predictive model for microvascular invasion of hepatocellular carcinoma among candidates for either hepatic resection or liver transplantation[J]. Surgery, 2019, 165(6):1168-1175. DOI: 10.1016/j.surg.2019.01.012.
    [25]
    REGINELLI A, VANZULLI A, SGRAZZUTTI C, et al. Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies[J]. Med Oncol, 2017, 34(5):93. DOI: 10.1007/s12032-017-0949-7.
    [26]
    FAN J, YANG GS, FU ZR, et al. Liver transplantation outcomes in 1, 078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China[J]. J Cancer Res Clin Oncol, 2009, 135(10):1403-1412. DOI: 10.1007/s00432-009-0584-6.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (250) PDF downloads(20) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return